TWB
台寶生醫股份有限公司
TWB is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is TRK-001 (Phase 2; recruiting, Kidney Transplantation), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| TRK-001 | — | Phase 2; recruiting | Kidney Transplantation | Taiwan, United States | 2026-04-27 | Trial registry |
| IBES Tfr | — | — | — | — | — | Company disclosure |
| In vivo Treg | — | — | — | — | — | Company disclosure |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.